信达生物：三季度总产品收入超33亿元 同比增约40%

Group 1 - The core point of the article is that Innovent Biologics (01801.HK) reported a strong revenue growth of over RMB 3.3 billion in Q3 2025, reflecting approximately 40% year-on-year increase, driven by both oncology and comprehensive pipelines [1] Group 2 - The revenue growth is attributed to the dual drivers of oncology and comprehensive pipelines, indicating a robust performance in these segments [1]